Ovid joins the rare epilepsy race
Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.
Contingent value is back in vogue
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
Biogen pays $560m for an unproven Parkinson’s mechanism
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
A turn-up for Spectrum’s book
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
No buyout for Uniqure
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
